Biotech VC dips in 3Q, but 2014 on track to beat 2013
This article was originally published in Scrip
US venture capital investment in private biotechnology companies dipped to $1.05bn in the third quarter from $1.84bn in the second quarter, but venture funding in 2014 remains on track to beat the 2013 total and may exceed $5bn for the year – a total that hasn't been reached since 2008.
You may also be interested in...
Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.
Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.
First-ever BCMA inhibitor is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.